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Whe World Congress of Cardiology (WCC) held in Bar-
elona (4 days, September 2006) was a joint meeting of the
nnual congress of the European Society of Cardiology
ESC) and the World Heart Federation (WHF), with more
5,500 active participants attending from 135 different
ountries. In particular, 25% of the total attendance was
rom Africa, North and South America, and Asia.
A record number of 229 prearranged sessions (30 meeting
ooms running in parallel) were organized, including 12
ith other societies including the American College of
ardiology and the American Heart Association. A total of
0,594 abstracts from 94 different countries were submitted,
nd 3,917 (37%) were selected for presentation, including
4% dedicated to basic science.
The theme of the meeting was “cardiovascular disease and
geing.” The clinical profile and the management of elderly
atients with cardiovascular diseases (CVDs) were ad-
ressed in 18 pre-arranged sessions and 125 scientific
bstracts. In this document, the Global Health Agenda (a
ummary of special reports from the WHF plenary sessions)
s discussed first, followed by the Euro Heart Survey
rogram and Hotline sessions. Thereafter, a summary of the
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Manuscript received October 11, 2006, accepted October 16, 2006.ost important contributions presented at the different
essions is provided.
HE GLOBAL HEALTH AGENDA
ardiovascular diseases are now the leading cause of death
orldwide claiming more than 17.5 million lives in 2005.
he greatest numbers of CVD deaths (80%) occur in low-
nd middle-income countries where the prevalence of CVD
s increasing at an alarming rate and health care resources
re limited. For inexplicable reasons, the United Nations
as not included CVD and chronic diseases among the
illennium development goals, designed to reduce poverty
nd promote health in developing countries by the year
015. Limited funds mean limited action directed at pre-
ention and control. This situation must be corrected if
rogress is to be recognized in preventing the early morbid-
ty and mortality from CVD worldwide.
In an adult population, poor health due to CVD threat-
ns sustainable economic growth and has an especially
rippling effect on countries with developing economies. In
000, the productive years of life lost due to CVD occurring
n the workforce of 5 selected countries included 1.1 million
n Brazil, 0.3 million in South Africa, 3.3 million in Russia,
.7 million in China, and 9.2 million in India for a total of
0.1 million. It is estimated that, between 2005 and 2015,
VD and its risk factors such as hypertension and diabetes
ill impose huge costs through lost productivity and reduce
he gross domestic product in most low- and middle-
ncome countries that are now experiencing rapid economic
rowth. Obesity and diabetes are 2 risk factors for CVD
hat are growing in prevalence worldwide. Their incidence
mong children is of particular concern as childhood obesity
enerally predicts adult obesity. Childhood obesity is in-
reasing across all continents such that 10% of the world’s
hildhood population is now overweight or obese. In many
esternized countries, the prevalence of children who areverweight is as high as 20% and increasing prevalence is
n
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etes in childhood, secondary to obesity, is increasingly
ommon in many countries, and its complications, espe-
ially the increased risk of CVD, greatly shorten the life
xpectancy for many in the obese childhood population.
Africa faces now a double burden, the combined epidem-
cs of communicable diseases and emerging chronic diseases.
n Africa, CVD is major component of chronic diseases and
ncludes hypertension, stroke, cardiomyopathy, rheumatic
eart disease, and the increasing prevalence of ischemic
eart disease. Prevention must be the cornerstone of effec-
ive clinical and public health intervention. For example,
nly 60 children need to be treated with penicillin to prevent
case of rheumatic heart disease. Hypertension prevention
nd control can eliminate most stroke morbidity and mor-
ality. In Africa, increased emphasis must be made on CVD
isk factor awareness, surveillance, advocacy, and adherence
o best practices.
Worldwide, more than 15 million people have rheumatic
eart disease and at least 350,000 related deaths occur
early. The WHF sponsors demonstration sites and training
orkshops in the South Pacific and is and is developing sites
n Africa to assist with the development of critically needed
egister-based programs. Portable echocardiography is in-
reasingly available in countries with developing economies
nd is the only reliable method for the detection of
ubclinical rheumatic heart disease. Vaccines for the preven-
ion of rheumatic heart disease are now in early clinical trials
nd hold great potential if effective, safe, and affordable.
The mortality from CVD in China has more than
oubled during the last 20 years. TheWHF sponsors a large
econdary prevention program involving hospitals in all 31
rovinces and regions of China. The goal is to improve
tilization of secondary prevention therapies known to
mprove outcomes for patients hospitalized with CVD.
urrent utilization of these therapies is being determined
or hospitals in each region, after which strategies designed
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACS  acute coronary syndrome
CRT  cardiac resynchronization therapy
CVD  cardiovascular disease
ESC  European Society of Cardiology
MRI  magnetic resonance imaging
MSCT  multislice computed tomography
NYHA  New York Heart Association
PCI  percutaneous coronary intervention
SPECT  single-photon emission computed
tomography
STEMI  ST-segment elevation myocardial
infarction
VHD  valvular heart disease
WCC  World Congress of Cardiology
WHF  World Heart Federationo operate under limited resources will be initiated to amprove their implementation. It is anticipated that this
rogram will provide important information to assist in
mproving the outcome for patients with CVD in China
nd serve as a model for other low- and middle-income
ountries.
URO HEART SURVEY
he Euro Heart Survey program of the ESC provides
ystematic information on the management of patients with
VD in clinical practice in Europe. During the WCC
006, data of current surveys were presented in 5 symposia
overing the following topics: ageing and CVD, acute
oronary syndromes (ACS), heart failure, percutaneous
oronary intervention (PCI), and atrial fibrillation.
ging and CVDs. The population is ageing rapidly, with
3.7% of the European population aged 65 years or older,
hich is twice the world level. With age, the prevalence of
eath due to CVD increases steeply up to about 40% in the
lderly. In the second Euro Heart Survey on ACS, 40% of
onsecutive patients were older than 70 years. The elderly
ess often received reperfusion and acute adjunctive treat-
ent and had 3 times higher 30-day and 1-year mortality
han patients younger than 70 years. In the PCI survey, 19%
f all patients undergoing PCI were older than 75 years
mean age 79 years), with 75% having multivessel disease.
lthough the rate of complications was low, the elderly
uffered from bleeding and renal failure requiring dialysis
wice as often as younger patients. In the survey on valvular
eart disease (VHD), the most common valve diseases were
ortic stenosis and mitral regurgitation. In patients older
han 75 years, surgery was denied in 33% with severe aortic
tenosis and in 64% with severe mitral regurgitation.
CS. The comparison of the 2 Euro Heart Surveys on
CS-I in 2000 and ACS-II in 2004 demonstrated a
ignificant improvement in adherence to current treatment
uidelines with an increase of primary reperfusion for
T-segment elevation myocardial infarction from 56% to
4% and a shift from thrombolysis to primary PCI. Ad-
unctive medical treatment with beta-blockers, angiotensin-
onverting enzyme (ACE) inhibitors, clopidogrel, and st-
tins improved over the years. This improvement in
dherence to guidelines was associated with a trend towards
ower 30-day and 1-year mortality in clinical practice.
CI. The Euro Heart Survey on PCI enrolled 13,152
onsecutive patients in 134 centers of 39 ESC member
ountries between June 2005 and January 2006. The indi-
ations for the intervention were ACS in 57% of all patients.
wo-thirds of the patients undergoing PCI had multivessel
isease. However, in 69% of all cases, 1 lesion was treated,
robably reflecting incomplete revascularization. Stenting
ate in clinical practice was 93%; a total of 41% of patients
eceived drug-eluting stents with great variation between
ountries from below 10% up to 80%. The use of diagnostic
evices like intravascular ultrasound or pressure/flow wires
nd therapeutic devices like distal protection devices,
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Highlights of 2006 ESC Scientific Sessions December 19, 2006:2564–74hrombectomy devices, or rotablation was below 2% in the
verall population.
eart failure. The Euro Heart Survey on Heart Failure-II
nrolled patients with acute heart failure. Patients with
cute de novo as compared with acute decompensated
hronic heart failure had higher in-hospital mortality but
ower 1-year mortality. In these subgroups, chronic treat-
ent with beta-blockers and ACE inhibitors was associated
ith a significant reduction in 1-year mortality in unselected
atients in clinical practice. The medical treatment with
CE inhibitors, beta-blockers, and spironolactone in pa-
ients with heart failure significantly improved between the
Euro Heart Surveys on heart failure in 2000 and 2004.
owever, the used dosages of particularly beta-blockers and
CE inhibitors remained unchanged over the years at a
ean of only 50% of the recommended dosages derived
rom randomized controlled trials.
trial fibrillation. The Euro Heart Survey on atrial fibril-
ation revealed an under-treatment with long-term oral
nticoagulation in 26% of patients with atrial fibrillation.
his under-treatment was associated with a 2-fold increase
f thromboembolic events during 1-year follow-up. Espe-
ially in paroxysmal atrial fibrillation, the rate of stroke
ithin 1 year after pharmacologic or electrical cardioversion
as 3-fold higher than in persistent atrial fibrillation. This
igher incidence in stroke may have been related to a lower
ate of effective oral anticoagulation and a higher rate of
epeated cardioversions in this patient subgroup.
OTLINES, NON-INTERVENTIONAL
he 2-year follow-up results of the international REACH
REduction of Atherothrombosis for Continued Health)
egistry were presented, and international differences were
ddressed. The study included more than 68,000 patients
nrolled from 5,592 sites of 44 countries. This worldwide
egistry provides detailed information on risk factors, med-
cal treatment, achievement of therapeutic goals, and long-
erm outcome among different health care systems. Results
howed that, during 2-year follow-up, 20% of patients
uffered a major event or were hospitalized. The incidence
f cardiovascular death was 2.6% as compared with 6.2% for
he combined end point of cardiovascular death, stroke, or
yocardial infarction. Patients from Eastern Europe or the
iddle East had the highest incidence of events, with 33%
f the enrolled patients suffering a major event.
In the WAVE (Warfarin Antiplatelet Vascular Event)
tudy, patients with peripheral atherosclerotic disease from
0 centers in 7 countries were randomized to receive either
ntiplatelet therapy only (n  1,081) or antiplatelet therapy
ombined with oral anticoagulants (n  1,080). Patients
ith peripheral atherosclerotic disease are at increased risk
f late cardiovascular events, and the combined strategy has
een shown to be effective in patients with CVD. The
spirin dose varied between 81 and 325 mg. The oral
nticoagulant therapy was of moderate intensity aiming at wn international normalized ratio of 2 to 3. Results after 42
onths follow-up showed that 12.2% of patients with
ombined therapy suffered cardiovascular death, infarction,
r stroke compared with 13.3% of patients receiving aspirin
nly (p  0.49). In addition, 4% of the patients with
ombined therapy experienced life-threatening bleeds com-
ared with 1.2% in the aspirin only group (p  0.001). It
as concluded that the combined therapy offered no bene-
cial effect (with higher bleeding risk) in patients with
eripheral atherosclerotic disease.
The effect of homocysteine lowering in patients with
hronic vascular disease was studied in the HOPE-2 (Heart
utcomes Prevention Evaluation) trial. A total of 5,522
atients were randomized to treatment with folic acid (2.5
g), vitamin B6 (50 mg), and vitamin B12 (1 mg), or
lacebo. During 5-year follow-up, no difference was ob-
erved in cardiovascular death, infarction, or stroke in
reated patients (18.8%) or the placebo group (19.8%),
ndicating no beneficial effect of vitamin supplementation.
The CIBIS (Cardiac Insufficiency Bisoprolol Study)-III
valuated the optimum sequence of initiating treatment of
eart failure patients: starting with bisoprolol or enalapril.
n a subanalysis, the incidence of sudden death was com-
ared. A total of 1,010 patients with moderate heart failure
ere randomized to either starting with bisoprolol or
nalapril for 6 months, followed by their combination up to
4 months. During the first year, the sudden death rate was
arginally lower (3.1% vs. 5.7%, p  0.049) in the patients
eceiving bisoprolol first. However, during the entire study
eriod, no differences in the incidence of sudden death were
bserved. The results of initiating therapy with bisoprolol
re promising, but need confirmation in a larger population.
The effect of patent foramen ovale closure in patients
ith invalidating migraine has been investigated in the
IST (Migraine Intervention with STARFlex Technology
NMT Medical, Inc., Boston, Massachusetts]) trial. Pa-
ients were randomly assigned to a closure device or sham
ntervention. The study confirmed for the first time the high
ate of right-to-left shunt in patients with migraine (37%).
he primary end point, complete cessation of migraine, was
ot reached. A significant decrease in the total disease
urden was shown: 42% of patients with closure device
eported a decrease of at least 50% of the number of
eadache days, as compared with 23% with sham operation.
hese results triggered the launch of the MIST-II trial that
ill aim at using a resorbable closure device in 600 patients.
OTLINES, INTERVENTIONAL
he effect of age on the 1-year mortality after revascular-
zation in patients with multivessel coronary artery disease
as analyzed in the ARTS (Arterial Revascularization
herapy Studies) trials. Among the patients who underwent
ypass surgery, a trend towards an increased mortality with
ge was observed whereas this trend was not seen after PCI
ith bare-metal or drug-eluting stents.
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tent (Xience V stent; Abbott, Abbott Park, Illinois) was
ested against the paclitaxel-eluting stent (Taxus, Boston
cientific, Natick, Massachusetts) in patients with 1 or 2
tenoses. At 6 months, the everolimus stent was associated
ith a significantly smaller neointimal hyperplasia than the
aclitaxel-eluting stent. In 30% of lesions, the everolimus-
luting stent was associated with a negative angiographic
ate loss. The study was not powered to draw conclusions on
linical outcome.
Paralleling the development of new drug-eluting stents,
everal recent bare-metal stents have good track records in
erms of clinical outcome. This was illustrated by a prospec-
ive randomized trial in which the rate of major adverse
ardiac events was equally low after implantation of a
iolimus A9 eluting stent (5.4%) or bare-metal stent (5.0%).
The 18-month clinical outcome data of the Basket (Basel
tent Cost-Effectiveness Trial) study were reported. The
rial consists of a randomized comparison between drug-
luting stents (sirolimus- and paclitaxel-eluting stents) and
are-metal stents in 826 consecutive patients. The data
uggest that the benefit (in terms of total major adverse
ardiac events, and survival free of death or infarction) is
ignificantly larger with drug-eluting stents as compared
ith after bare-metal stents in small vessels (3 mm) or
ypass grafts. This advantage was no longer present or even
eversed in larger native vessels (3 mm). A detailed
ost-effectiveness study performed on the same cohort of
atients indicates that, if drug-eluting stents are used in all
atients, incremental cost-effectiveness ratio to avoid 1
ajor adverse cardiac event is high (€50,000). In contrast,
he incremental cost-effectiveness ratio to avoid 1 major
dverse cardiac event is favorable if drug-eluting stents are
sed only in patients with small stents or bypass graft
tenting.
The 5-year clinical outcome data of the patients included
n the RAVEL (Randomized Study with Sirolimus-Coated
x Velocity Balloon-Eexpandable Stent in the Treatment of
atients With De Novo Native Coronary Artery Lesion)
tudy have been presented. The study, which was powered
or an angiographic end point had shown that sirolimus-
luting stents virtually abolish neointimal hyperplasia: after
months, the angiographic late loss was 0.01 mm after
irolimus-eluting stenting versus 0.80 after bare-metal
tenting. After 5 years, the number of target vessel revascu-
arizations remains significantly lower in the sirolimus-
luting stent group than in the bare-metal stent group. In
ontrast, a trend towards a higher rate of death or infarction
as reported.
Two meta-analyses sparked a lot of discussion. Both are
ased on earlier randomized studies comparing sirolimus- or
aclitaxel-eluting stents to their bare-metal counterpart
more than 7,000 patients). The first meta-analysis showed
relative excess in combined death or Q-wave myocardial
nfarction in patients who received a first generation drug-
luting stent. The second meta-analysis focused on the rate sf non-cardiac death, which tended to be higher with first
eneration drug-eluting stents (particularly sirolimus-
luting stents) than bare-metal stents. However, before
rawing definitive conclusions, more details on the exact
ethodology used for these meta-analyses should be
waited. Nonetheless, the data presented during the meet-
ng points towards a more tailored use of bare-metal and
rug-eluting stents.
CS
iagnosis. Early diagnosis and triage are essential in treat-
ent of ST-segment elevation myocardial infarction
STEMI). A British registry revealed that delay of throm-
olysis was a predictor of increased mortality in STEMI
atients (1). Time-to-reperfusion treatment can be reduced,
hen the patients can be directed to primary PCI based on
re-hospital diagnosis on-site or by wireless electrocardio-
ram transmission to the PCI center (2,3). Applying tele-
ardiology to a large region also shortened diagnostic delay
nd diminished the number of improper hospitalizations (4).
herapy. A French registry showed that guideline-
ecommended therapy was underutilized in acute infarction
atients older than 80 years (5).
New data from the OASIS (Organization to Assess
trategies for Ischemic Syndromes)-5 study revealed that
he 50% decrease in early bleeding with fondaparinux
ompared with enoxaparin was consistent regardless the use
f unfractionated heparin, and that this lower risk of
leeding was associated with reduced long-term mortality
6). A randomized trial in 393 patients with non-STEMI
reated with aspirin, clopidogrel, and invasive therapy re-
ealed no benefit of eptifibatide (7).
In the recent publications, neither distal protection nor
hrombectomy improved outcome during primary PCI.
ccordingly, a meta-analysis showed no benefit of throm-
ectomy and distal protection (8). However, in a random-
zed trial including 368 STEMI patients, thrombus aspira-
ion before primary PCI improved myocardial microcirculation
s evaluated by myocardial blush rate (9).
Registries suggested that clopidogrel is beneficial in the
reatment of STEMI (10,11). In a randomized study in
atients undergoing PCI, a maintenance dose of 150 mg
aily was shown to inhibit adenosine-diphosphate-induced
latelet aggregation more efficiently than the usual dose of
5 mg daily (12).
rognosis. Electrocardiogram data from the ASSENT
ASsessment of Safety and Efficacy of New Throm-
olytic)-4 PCI study, where facilitated primary PCI with
enecteplase was found to be associated with a worse
utcome than primary PCI without thrombolysis, revealed
hat resolution of ST-segment elevation at 60 min after
andomization occurred more often in patients treated with
acilitated PCI (13). However, at the time interval from 60
o 180 min, tenecteplase-treated patients had less ST-
egment resolution, and this was associated with an in-
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Highlights of 2006 ESC Scientific Sessions December 19, 2006:2564–74reased incidence of reinfarction and may explain the rather
nexpected poor outcome in patients treated with facilitated
CI (13).
Reperfusion arrhythmias after primary PCI were associ-
ted with a favorable prognosis (14). Acute coronary syn-
rome patients presenting with left bundle branch block
ave a higher mortality than patients presenting with
T-segment elevation (15).
Analysis of the combined data from the OASIS-5 and -6
rials showed that low baseline hemoglobin levels were
elated to a poor outcome and risk of bleeding, which was
ignificantly lower with fondaparinux than with enoxaparin/
nfractionated heparin/placebo (16). Also, in STEMI pa-
ients undergoing primary PCI (17,18), anemia at presen-
ation was associated with poor outcome. An increased
hite cell count at baseline was also associated with poor
utcome in patients undergoing primary PCI (19).
EART FAILURE
substantial number of registries on heart failure were
resented, with a focus on the elderly patients (see the
receding text Euro Heart Survey). The main conclusions of
hese trials were that heart failure is frequent among the
lderly and that these patients are still poorly treated
lthough they would equally benefit from life-saving ther-
pies as compared with younger patients. In 1 registry,
onsisting of 1,054 heart failure patients most of which were
lder than 70 years, adherence to pharmacotherapy as
ecommended by the ESC guidelines was a strong and
ndependent predictor of superior survival, and this
enefit was irrespective of age, gender, and left ventric-
lar function (20).
Next, more pathophysiological studies were presented. It
s known that both the immune system and autonomic
mbalance are key elements of the complex pathophysiology
f heart failure. These factors are traditionally considered in
solation, but new evidence was presented supporting that
mmune dysfunction (as evidenced by elevated levels of
roinflammatory cytokines) correlated with depleted vagal
one (21). In addition, an increase in cholinergic signaling
ith pirydostigmine (reversible acetylcholinesterase inhibi-
or) improved autonomic balance with concomitant atten-
ation of immune activation of circulating immunocompe-
ent cells (21). Whether restoration of parasympathetic
ystems will ultimately lead to restoration of autonomic and
mmune control needs further study.
Testosterone deficiency is a component of impaired
nabolic function in men with heart failure and predicts
xercise intolerance and poor quality of life. A double-blind,
lacebo-controlled parallel study of testosterone replace-
ent therapy (up to 12 months) at physiological doses was
ndertaken in 76 men with symptomatic heart failure (New
ork Heart Association [NYHA] functional class II to IV,
eft ventricular ejection fraction 32%) (22). The therapy was
afe and significantly improved heart failure symptoms, gunctional capacity, and increased handgrip strength. The
echanisms underlying these findings merit further study.
Anemia is frequently observed in heart failure and is
ssociated with increased morbidity and mortality. Prelim-
nary studies have suggested that correction of anemia with
rythropoiesis-stimulating proteins may improve exercise
apacity, symptoms, and quality of life. Combined analysis
f 2 randomized, double-blind, placebo-controlled studies
as presented, in which 266 anemic patients (hemoglobin
evel 9.0 g/dl and 12.5 g/dl) with symptomatic heart
ailure were treated with darbepoetin alfa (long-acting
rythropoiesis-stimulating protein) and 209 received pla-
ebo (23). Therapy with darbepoetin alfa was well-tolerated,
ncreased and maintained hemoglobin level within the
arget range, but did not significantly improve quality of life
r symptoms. Interestingly, however, there was strong trend
owards improvement in composite outcome of morbidity
nd mortality. In another study, 35 symptomatic heart
ailure patients with iron deficiency were randomly assigned
o a 16-week therapy with intravenous iron sucrose versus
o treatment (24). Iron repletion with iron sucrose was safe,
ell tolerated, and associated with improvements in exercise
apacity and symptoms. Of note, the benefits were partic-
larly evident in anemic patients, showing a mean increase
n peak VO2 of 4.0 ml/kg/min.
Whether targeting inflammation with a novel, broad
pectrum immune modulating therapy would reduce mor-
ality and hospitalization rate in heart failure patients was
valuated in the ACCLAIM (Advanced Chronic Heart
ailure Clinical Assessment of Immune Modulation Ther-
py) trial. Immune modulating therapy was based on the
ovel device—Celacade System (Vasogen Inc., Mississauga,
ntario, Canada)—that delivers controlled oxidative stress
o a patients’ blood sample ex vivo, and results in apoptosis
f autologous cells; the blood sample is then administered
ntramuscularly, which subsequently triggers an anti-
nflammatory response. The ACCLAIM trial randomized
ore than 2,400 heart failure patients (70% in NYHA
unctional class III to IV, left ventricular ejection fraction
3%, all with optimized medical therapy with 94% receiving
CE inhibitors and/or angiotensin receptor blockers and
7% receiving beta-blockers) to treatment with either im-
une modulating therapy or placebo. Immune modulating
herapy appeared safe and well-tolerated, but the primary
nd point (mortality and cardiovascular hospitalization) was
ot met. However, immune modulating therapy was effec-
ive in 2 pre-specified subgroups: patients with NYHA
unctional class II and patients without history of previous
nfarction.
YPERTENSION
pidemiologic studies focused on the prevalence and con-
rol of risk factors. A large annual survey (Cardiomonitor) in
atients with CVD was presented, with data obtained by
eneral practitioners and cardiologists from all over the
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hat only 1 of 5 patients in Europe and 2 of 5 in the U.S.
ad well-regulated systolic blood pressure (130 mm Hg),
ndicating that, with the rising incidence of diabetes world-
ide, there is also urgent need for better blood pressure
ontrol.
Hypertension is in large part determined by genetic
actors. In 215 young patients with type 1 diabetes, it was
hown that blood pressure progression was related to an-
iotensinogen gene polymorphism (26). Another study
evealed that the atrial natriuretic peptide promoter gene
ariant was associated with higher blood pressure at young
ge (27). These individuals also showed a predisposition to
evelop cerebrovascular events.
Pathophysiological mechanisms in hypertension were
lso investigated. High adrenergic tone was associated with
neuroplastic reduction in sympathetic nerve density, with
uppression of nerve growth factor being the possible
ediating mechanism (28). In another study, an altered
tructure of subcutaneous small resistance arteries (i.e.,
ncreased wall thickness to lumen diameter ratio) was
hown to be associated with increased morning rise of
lood pressure, a factor of enhanced risk, possibly because
f amplification of hypertensive stimuli in the early
orning (29).
Among indicators of preclinical organ damage in hyper-
ension, the importance of left ventricular hypertrophy as an
ndependent risk factor is well recognized. The results of the
IFE (Losartan Intervention For Endpoint reduction in
ypertension) study confirmed that left ventricular geometry
uring treatment adds information on risk of major cardio-
ascular events (with concentric geometry associated with
he highest risk) (30).
In general, prevention or regression of organ damage
hould be considered a specific goal of antihypertensive
reatment. New therapeutic approaches were proposed. An
nhibitor of rho-kinase was shown effective for preventing
enal and cardiac damage in a rat-model of malignant
ypertension (31). In man, the efficacy and safety of
liskiren (the first of a new class of orally effective renin
nhibitors) were assessed in a pooled analysis from large
andomized, double-blind, clinical studies, involving more
han 700 patients. It was shown that doses of 150 to 300 mg
aily effectively reduced blood pressure without significant
ide effects (32).
Hypertension is often associated to metabolic risk factors
nd abdominal obesity. Pooled data from trials with rimon-
bant (the first selective cannabinoid CB1 receptor blocker)
onfirmed its efficacy in improving glucose and lipid me-
abolism and in reducing body weight over 1 year of
reatment (33). The ASCOT (Anglo-Scandinavian Cardiac
utcome Trial) study confirmed that treatment with diuret-
cs and beta-blockers is mostly associated with a greater
ncidence of new-onset diabetes, particularly in those at
igher risk. Finally, the results of the EUROACTION
rogram have shown that involving multidisciplinary teams ln delivering the prevention message leads to a significant
eduction in cardiovascular risk factors as compared with the
sual preventive approach. This is a strong message, indi-
ating that it is achievable to improve significantly the
ontrol of risk factors and, hence, the burden of CVD in
linical practice.
LECTROPHYSIOLOGY AND PACING
ardiac resynchronization therapy (CRT). Many origi-
al scientific contributions were dedicated to CRT. Further
nalysis of the CARE-HF (Cardiac REsynchronization-
eart Failure trial) data aimed at prediction of sudden
ardiac death (34). Severe mitral regurgitation at 3 months
ollow-up appeared a significant predictor of sudden death
hereas CRT was protective against sudden death.
In another subanalysis of the CARE-HF study, it was
hown that diabetic patients had similar benefit from CRT
s compared with non-diabetic patients (35).
Randomized studies on CRT in atrial fibrillation are
parse, but observational studies suggest similar benefit to
atients in sinus rhythm. An unresolved issue is whether
atients with atrial fibrillation should undergo atrioventric-
lar node ablation to ensure capture. In a 4-year open study
ith 243 heart failure patients, superior survival was dem-
nstrated in patients who underwent atrioventricular node
blation (annual mortality 4.3% vs. 15.2% in non-ablated
atients, p  0.001) (36).
trial fibrillation. The new American College of Cardi-
logy/American Heart Association/ESC guidelines on
anagement of atrial fibrillation indicate that high-risk
actors for thromboembolism are previous stroke, transient
schemic attack or embolism, mitral stenosis, and prosthetic
alves. Moderate risk factors are age 75 years, hyperten-
ion, heart failure, left ventricular ejection fraction 35%,
nd diabetes. Oral anticoagulation is recommended (class I
ndication) in the presence of any high-risk factor or more
han 1 moderate-risk factor. The risk/benefit of oral anti-
oagulation in relation to these risk factors was addressed in
90 elderly patients (median age 82 years) (37). For elderly
atients with only 1 moderate risk factor, the number
eeded to treat (n  58) and harm (n  51) was relatively
ow, and the indication for oral anticoagulation may be
uestionable. For patients with 4 moderate- and 1 high-risk
actor, the number needed to treat (n  16) and to harm
n  29) was relatively low indicating that oral anticoagu-
ation should be individualized in these elderly patients. For
he remaining patients with 2 to 3 moderate risk factors,
ral anticoagulation should be provided.
The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial
ith Irbesartan for Prevention of Vascular Events-
arfarin) substudy reported on the risk of stroke or
hromboembolism in paroxysmal versus persistent/
ermanent atrial fibrillation (38). These patients had on the
verage 1.7 to 2 moderate-risk factors for thromboembo-
ism. The risk of stroke or thromboembolism was compa-
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Highlights of 2006 ESC Scientific Sessions December 19, 2006:2564–74able in both groups (2.0 in paroxysmal vs. 2.2 in persistent/
ermanent/100 person-years), and oral anticoagulation in
oth groups was clearly superior to the combination of
lopidogrel and aspirin in reducing the risk.
Polyunsaturated fatty acids reduced the risk for ventric-
lar arrhythmias and sudden death in post-myocardial
nfarction patients. The properties of these fatty acids in
educing the risk of atrial fibrillation relapse after cardio-
ersion was evaluated (39); the 1-year relapse risk after
ardioversion was 23% in patients who received 1 g fatty
cids in addition to conventional therapy, as compared with
6% in a control group (p  0.001).
evices and ablation therapy. The PEOPLE (Prospec-
ive Evaluation Of Pacemaker Lead Endocarditis) study (44
enters, 6,134 device implantations) focused on the need for
ntibiotic prophylaxis during device implantation (40). It
as shown that the risk of infection was significantly lower
n patients receiving antibiotic prophylaxis (1.3% vs. 0.6%, p
0.03) (40).
In ablation therapy, recurrence after radiofrequency cath-
ter ablation of accessory pathways occurs and generally a
ime window of 30 min is used to ensure absence of
ecurrence. This was evaluated in 439 ablations (419 pa-
ients), and the risk of recurrence after 10 min was 0.4% and
.4% for left- and right-sided accessory pathways, respec-
ively, and 3.8% for superior, peri-His and medioseptal
ocations (41).
HD
he prevalence of VHD is rising, particularly in the ageing
opulation. This group is characterized by under-referral for
ppropriate intervention associated with excess morbidity
nd mortality.
Calcification underlies degenerative VHD, and numerous
roups seek underlying mechanisms. Human valve cells
xposed to osteogenic media demonstrated increased activ-
ty of alkaline phosphatase, suggesting differentiation to an
steoblastic phenotype. These effects are abolished by ator-
astatin, which decreased cytokines and increased adenosine
riphosphate breakdown and adenosine formation (42).
imilarly, in patients with aortic stenosis, levels of fetuin A
an inhibitor of vascular/soft-tissue calcification already
mplicated in vascular disease in dialysis recipients) were
hown to inversely correlate with valve calcification and
redicted disease progression (43,44). While clinical data
re conflicting and randomized trials awaited, increased
nderstanding of these pathways may demonstrate novel
herapeutic targets.
Difficult clinical situations are commonplace in regur-
itant VHD where a long symptom-free period often
ccompanies irreversible decline in left ventricular func-
ion. Although international guidelines provide criteria
or early surgery, additional information can be obtained
y indexing left ventricular end-systolic diameter to body
urface area (45). bPercutaneous mitral commissurotomy is the treatment of
hoice for patients with mitral stenosis suitable for the
rocedure. Single-center data concerning 3,709 patients
emonstrated good immediate results in 89% of patients
ith low mortality (0.4%), technical failure (1.1%), or severe
itral regurgitation (4.4%) (46). These excellent results
ere applicable worldwide despite varying patient charac-
eristics (47), and long-term follow-up was similar to closed
ommissurotomy, the surgical alternative (48).
In addition, 1 study reported on the successful application
f percutaneous mitral valve repair in 12 subjects with severe
egurgitation and preserved left ventricular function (49).
nother study was presented on 36 patients with severe
ortic stenosis and advanced comorbidity who underwent
uccessful percutaneous valve implantation; the adverse
vent rates were 19% at 1 month and 28% at 6 months
ollow-up, without valve migration (50). The percutaneous
alve techniques are promising, but more data are needed.
Numerous factors predict adverse outcome in infective
ndocarditis. It was shown that diabetic patients had an
ncreased incidence of staphylococcal and enterococcal in-
ections with a higher mortality and incidence of heart
ailure and multi-organ failure (51). In another registry, an
ncidence of cerebrovascular complications of 22% in infec-
ive endocarditis was demonstrated using computed tomog-
aphy of the brain (52). The benefits of early surgery in these
igh-risk patients were confirmed in summative data from
he international collaboration on endocarditis (53).
MAGING: ECHOCARDIOGRAPHY
ifferent studies on new technical developments and new
linical applications were presented. A contrast echocardio-
raphic study evaluated the value of myocardial viability to
redict outcome in patients with acute infarction. A total of
6 patients underwent vasodilator low power myocardial
ontrast echocardiography at 7  2 days after thrombolysis
54). It was shown that the extent of residual myocardial
iability was the only independent predictor of mortality
nd reinfarction.
Strain rate imaging was used to discriminate different
egrees of myocardial necrosis and to identify segments
ith potential functional recovery in 18 patients with acute
nterior infarction; the results were compared with contrast-
nhanced magnetic resonance imaging (MRI) (55). Strain
ate imaging could differentiate between non-transmural
nd transmural necrosis. The sensitivity, specificity, and area
nder the receiver operator characteristic curve to identify
hose segments with potential functional recovery (defined
s 50% of scar tissue on contrast-enhanced MRI) were
4%, 71%, and 0.76, respectively. Strain rate imaging
ppears promising to evaluate the transmurality of necrosis
nd detect non-viable myocardium after acute infarction.
Real-time 3-dimensional echocardiography was used to
ssess the effects of CRT (56). Twenty patients were studied
efore and 6 months after CRT implantation. The dyssyn-
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December 19, 2006:2564–74 Highlights of 2006 ESC Scientific Sessionshrony index, defined as the standard deviation of the time
t takes for each of the 16 left ventricular segments to reach
heir minimum volume, as well as the left ventricular
jection fraction were calculated. From the analysis of the
egional volumes, an evaluation of the total volume change
f the left ventricular segments that present with delayed
ontraction (“total delayed volume”) was also feasible. In the
esponders (n 14), significant reductions were observed in
he left ventricular volumes and the dyssynchrony index
ith an increase in left ventricular ejection fraction (9 2%)
fter CRT. A significant reduction in the total delayed
olume was also observed, and a strong correlation was
emonstrated between the dyssynchrony index and the total
elayed volume. It was concluded that CRT has a signifi-
ant impact on several functional and anatomical echocar-
iographic left ventricular parameters. Novel variables, such
s the total delayed volume, could potentially offer a more
xtensive evaluation of the effects of CRT in the future.
Speckle-tracking echocardiography, which is a new
train-based method to assess left ventricular function, was
sed to evaluate left ventricular rotation and untwisting in
4 asymptomatic obese subjects (57); results were compared
ith standard tissue Doppler imaging. Obese subjects dem-
nstrated reduced systolic left ventricular torsion and basal
otation, but preserved systolic apical velocities. The
ntwisting rotational velocities in diastole were similarly
educed. Systolic longitudinal tissue velocity on tissue
oppler imaging correlated significantly with left ven-
ricular basal rotation and overall torsion. Left ventricular
orsion also correlated with waist. Basal rotation and left
entricular torsion were significantly reduced even in
atients without left ventricular dysfunction on tissue
oppler imaging. The novel speckle-tracking technique
ay be more sensitive to assess subclinical myocardial
isease in obese patients as compared with standard tissue
oppler imaging.
MAGING: NUCLEAR CARDIOLOGY,
RI, AND COMPUTED TOMOGRAPHY
he strength of nuclear cardiology remains risk stratifica-
ion. The prevalence of perfusion abnormalities on single-
hoton emission computed tomography (SPECT) imaging
n patients with diabetes was addressed in a European
ulticenter registry (58). Diabetic patients were prospec-
ively recruited from 17 centers in 6 European countries;
39 patients underwent a rest-stress perfusion-gated
PECT examination. A history of CVD, male gender, body
ass index25 kg/m2, alcohol consumption were indepen-
ent predictors of abnormal SPECT studies. It was con-
luded that gated SPECT imaging permits further risk
tratification in addition to the traditional risk factors in
atients with diabetes.
Two studies used nuclear imaging to evaluate novel
herapies. Metabolic imaging with F18-fluorodeoxyglucose
as used to detect viability and scar tissue to better predict pesponse to CRT (59). Sixty-one consecutive patients with
dvanced heart failure, left ventricular ejection fraction
35%, QRS duration 120 ms, and chronic CVD were
ncluded. The presence of myocardial viability was directly
elated to an increase in left ventricular ejection fraction
fter 6 months of CRT. The optimal cutoff value to predict
linical response to CRT was identified at an extent of 11
iable segments or more (in a 17-segment model), yielding
sensitivity of 74% and a specificity of 87%.
A second study evaluated the effect of intracoronary
nfusion of autologous bone marrow stem cells in patients
ith acute infarction (60). Patients were randomized either
o cell therapy or a control group. The patients who received
ell therapy showed superior left ventricular function and
erfusion as compared with control subjects at 12 months
ollow-up.
Magnetic resonance imaging has become the gold stan-
ard for assessment of cardiac function and myocardial scar
y contrast-enhanced imaging. Despite excellent diagnostic
ccuracy of contrast-enhanced MRI, the prognostic signif-
cance is unknown. This was addressed in a multicenter trial
61). In 1,493 patients, the prognostic value of MRI
ssessment of left ventricular ejection fraction and scar tissue
as evaluated. The median follow-up time was 2.4 years,
nd the primary end point was all-cause mortality. On
nivariate analysis, the only clinical predictors were older
ge and history of CVD. Magnetic resonance imaging
redictors were left ventricular ejection fraction and the
resence/extent of scar tissue. On multivariate analysis, age,
eft ventricular ejection fraction, and extent of scar tissue
ere independent predictors of all-cause mortality.
Similarly, the prognostic value of contrast-enhanced
RI was assessed in 101 patients with dilated cardiomy-
pathy (62). Mid-wall fibrosis was present in 35% of
atients, was the single significant predictor of death/
ospitalization, but also predicted sudden cardiac death/
entricular tachycardia. Both of these studies (61,62) sug-
est a potential role for MRI in risk stratification of patients
ith ischemic or dilated cardiomyopathy.
Multislice computed tomography (MSCT) permits non-
nvasive assessment of the coronary arteries. This concept
as applied in patients referred for valve surgery (63). In
hese patients, MSCT was used to exclude or detect CVD,
o decide whether valve surgery should be combined with
ypass surgery or not. In 70 patients, the sensitivity and
pecificity of MSCT to detect significant stenoses were
xcellent, indicating that MSCT may replace invasive an-
iography in these patients.
In another study, the accuracy of 64-slice MSCT for
ssessment of plaque composition was compared with in-
ravascular ultrasound (64). Multislice computed tomogra-
hy correctly detected 83% of non-calcified plaques, 97% of
ixed plaques, 95% of calcified plaques. Multislice com-
uted tomography may, thus, be helpful in assessment of
laque composition.
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Highlights of 2006 ESC Scientific Sessions December 19, 2006:2564–74In addition to evaluation of coronary arteries, MSCT also
ermits detection of potential aortic valve stenosis (65). In
0 patients with aortic stenosis, the valve area on MSCT
as closely related to echocardiography.
ASIC SCIENCE
n the area of stem cell therapy, several experimental studies
eported on potential new sources of multipotent cells for
ardiac repair, such as cells from amniotic fluid (66), adipose
issue (67), or testis (68). The spermatogonial cells seem to
ave a similar potential as embryonic stem cells for differ-
ntiation into functional cardiac myocytes, a desired end
oint not as easily reached by cells from other sources.
re-differentiation may facilitate the incorporation of em-
ryonic cells into the myocardium (69), but for xenogeneic
ransplant several immunological hurdles still need to be
aken (70), not counting the ethical issues to be addressed.
dult human cardiac tissue as obtained during atrial biop-
ies can also be a source of multipotent stem cells (71), or
ould contain cells that drive vasculogenesis as during
mbryonic development. Injection of such epicardium-
erived cells improved post-myocardial infarction remodel-
ng as shown in a murine model of myocardial infarction
72). The postulated paracrine effects of stem cell therapy
fter myocardial infarction were elegantly confirmed by the
mproved calcium handling of the native cardiac myocytes in
rat model (73). Targeting the matrix to prevent cardiac
ilation was proposed as an alternative to cellular replace-
ent therapy; alginate injection could significantly reduce
nfarct expansion and improve function (74).
Several studies also examined the signaling pathways for
ardiac hypertrophy as targets to prevent maladaptive re-
odeling. An interesting report described the protective
ffects of celecoxib, inhibiting Akt, on the development of
eart failure after aortic banding (75). In the area of vascular
iology, insights into the mechanisms of atherosclerosis
ave provided the basis for novel therapeutic approaches
uch as the testing of immunization against ox-low-density-
ipoprotein. Novel potential strategies could include the
p-regulation of “beneficial” immune cells. Gene therapy
as long aimed for increased or novel protein expression, but
ene silencing through interference with RNA translation
as in recent years opened new approaches. CC-chemokine
eceptor 2 and monocyte chemoattractant protein-1 play a
entral role in monocyte recruitment to sites of inflamma-
ion. Local application of lentiviral short hairpin RNA
gainst CC-chemokine receptor 2 could prevent vein graft
hickening in vivo (76). In the area of “classic” pharmacol-
gy, HMR1766, a drug that activates the nitric-oxide-
esistant oxidized soluble guanylate cyclase, could signifi-
antly reduce atherosclerotic plaque formation in the
poE/ mouse (77).
Identifying essential pathways promoting arteriogenesis
ould advance treatment of peripheral ischemic disease.
sing a genetic print of a model for enhanced collateralow, the actin-binding Rho activator was postulated to be a
ey regulator. Gene transfer in a hind-limb model of
schemia indeed enhanced arterial collateral perfusion by
ore than 70% (78).
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